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Detection of Hepatic VX2 Tumors in Rabbits:
Comparison of Conventional US and Phase-
Inversion Harmonic US During the Liver-
Specific Late Phase of Contrast Enhancement
Objective: To compare phase-inversion sonography during the liver-specific
phase of contrast enhancement using a microbubble contrast agent with conven-
tional B-mode sonography for the detection of VX2 liver tumors. 
Materials and Methods: Twenty-three rabbits, 18 of which had VX2 liver tumor
implants, received a bolus injection of 0.6 g of Levovist (200 mg/ml). During the
liver-specific phase of this agent, they were evaluated using both conventional
sonography and contrast-enhanced phase-inversion harmonic imaging (CE-
PIHI). Following sacrifice of the animals, pathologic analysis was performed and
the reference standard thus obtained. The conspicuity, size and number of the
tumors before and after contrast administration, as determined by a sonographer,
were compared between the two modes and with the pathologic findings. 
Results: CE-PIHI demonstrated marked hepatic parenchymal enhancement in
all rabbits. For VX2 tumors detected at both conventional US and CE- PIHI, con-
spicuity was improved by contrast-enhanced PIHI. On examination of gross spec-
imens, 52 VX2 tumors were identified. Conventional US correctly detected 18 of
the 52 (34.6%), while PIHI detected 35 (67.3%) (p < 0.05). In particular, conven-
tional US detected only three (8.3%) of the 36 tumors less than 10 mm in diame-
ter, but CE-PIHI detected 19 such tumors (52.8%) (p < 0.05) . 
Conclusion: Compared to conventional sonography, PIHI performed during
the liver-specific phase after intravenous injection of Levovist is markedly better
at detecting VX2 liver tumors. 
he detection of hepatic metastases is a crucial issue in the care of patients
with known primary cancers, and ultrasound is one of the diagnostic
modalities used for this purpose (1, 2). Ultrasound is known, however, to
have a relatively high false-negative rate for liver metastases (in the range of 33
47%), and its low sensitivity is related to its limited depiction of isoechogenic and
small liver metastases (3 7). Levovist (SHU 508 A; Schering AG, Berlin, Germany) is
an intravenously administered, galactose-based microbubble contrast agent that accu-
mulates in normal liver parenchyma during the late liver-specific phase, but which
spares focal lesions such as metastases (8 12). A number of studies have demonstrat-
ed that pulse- or phase- inversion harmonic imaging using Levovist improved the de-
tection rate of hepatic malignancies compared with conventional ultrasound imaging
(9 12). In those studies, however, the lack of firm evidence of the existence of small
liver metastases was the major limitation. 
The purpose of this study is to determine whether phase inversion harmonic imaging
(PIHI) during the late hepatic phase of contrast enhancement with Levovist depicts a
greater number of VX2 tumors, and ones that are smaller, than does conventional
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All protocols were approved by the Animal Use and
Care Committees of our universities. Twenty-three adult
male New Zealand White rabbits each weighing 3.0 3.5
(mean, 3.2) kg were included in this study, and were allo-
cated to either the VX2 tumor group (n=18) or the control
group (n=5). VX2 tumor cells were inoculated by laparoto-
my into the liver of rabbits in the tumor group. Animals in
the control group also underwent laparotomy, but without
tumor cell inoculation, and the sonographer was thus un-
aware, at the time of ultrasound examination, of whether a
VX2 tumor had been implanted. The rabbits were anes-
thetized by intramuscular injection of 50 mg/kg ketamine
hydrochloride (Ketamine ; Yuhan, Seoul, Korea) and 5
mg/kg xylaine (Rumpun ; Bayer Korea, Ansan, Korea) pri-
or to tumor inoculation and imaging studies. Booster injec-
tions of up to one-half the initial dose were administered as
needed. 
The VX2 tumor model was induced as already described
in previous reports (13, 14). Tumor cell suspension with an
estimated viable cell density of 5 10
6 cells/ml was
prepared using a freshly harvested VX2 tumor from a car-
rier rabbit and inoculated via laparotomy: during a 30-sec-
ond period, aliquots (0.1 0.3 ml of 5 10
6 viable cells/ml)
of VX2 tumor cells were slowly injected into the liver at
one or two locations. 
US Examinations
Fourteen days after tumor implantation, ultrasonograms
of the liver were obtained by one experienced radiologist.
The abdomen was shaved, and the rabbits were placed in
the supine position and attached to the investigation board.
Using individually optimized settings, a Sonoline Elegra
scanner (Siemens, Issaquah, Wash., U.S.A.) with a 7.5MHz
linear array and a dynamic range of 55 dB was used to ob-
tain conventional B-mode sonograms of longitudinal and
transverse liver sections.
After the completion of baseline scanning, one bolus of
Levovist (200 mg/mL, 3 cc) was injected into the lateral
ear vein of each rabbit at 1 mL/sec using a 21-gauge scalp
vein set (Green Cross Medical Co; Yongin, Kyungki,
Korea). To ensure that no residual contrast agent remained
in the intravenous line, 5-mL physiologic saline solution
was then immediately injected. Levovist uptake is liver
specific, and in order to allow sufficient time for the agent
to accumulate in normal liver parenchyma, gray-scale
pulse-inversion harmonic US data were recorded after a
delay of between 2.5 and 5 (mean, 4) minutes. For phase-
inversion scanning, “ensemble contrast imaging” software
(Siemens) was used with the following settings: insonating
frequency, 2.5 MHz; mechanical index, 1.0; frame rate,
more than 5 per second; parallel processing; and 2-5 focal
zones. The findings of a previous study (15) suggested that
these mechanical index values would provide marked en-
hancement of the liver parenchyma and thus lead to im-
proved tumor detection. 
For phase-inversion sonography, scanning involved a
controlled transverse sweep of the entire right lobe of the
liver from the diaphragm to the lower pole, lasting approx-
imately 3 4 seconds (16). When a sweep was completed,
the image was frozen and the individual frames were re-
viewed on a cine loop without time constraints. This was
followed by a transverse sweep of the left lobe using an
appropriate focal zone position. After these standardized
sweeps, additional phase-inversion scanning was per-
formed as required to visualize areas of the liver that might
not have already been sufficiently visualized.
Representative images were stored on the hard disc of the
US scanner. 
Image Interpretation 
The number, size, location, and echogenicity of each tu-
mor was recorded; size was determined in order to make a
lesion-to-lesion comparison between the US findings and
the pathologic specimen. Echogenicity was classified as hy-
po-, iso- or hyperechoic, as compared with hepatic
parenchyma. The findings of both baseline and phase-in-
version sonography were interpreted at the time of exami-
nation, without knowledge of whether or not VX2 tumors
had been implanted.
Tumor conspicuity, as seen at both baseline and PIHI,
was evaluated and compared at the time of scanning, and
decisions were made as to which modality provided better
results. Whether each modality enabled correct identifica-
tion of a rabbit with at least one implanted tumor was also
determined, and recorded as “yes” or “no.” In addition,
the ability of each modality to depict the correct number of
implanted tumors was compared. The sensitivity, specifici-
ty, and accuracy of both sonographic techniques for detect-
ing individual VX2 tumors were calculated using the refer-
ence standard (gross pathologic analysis).
Gross Pathologic Analysis
After US examination, rabbits were sacrificed by inject-
ing an overdose of Ketamine and Xylazine, and their livers
were harvested. Gross pathologic analysis of the liver pro-
vided a reference standard for comparing conventional
imaging and contrast-enhanced PIHI. All livers were serial-
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the US examinations, and the number and size of masses
were noted. The pathologic findings could thus be com-
pared directly with the tumor numbers and locations estab-
lished using conventional US and PIHI. The lesions detect-
ed were assigned to one of three groups: 10mm or more in
diameter, between 5 and 9 mm, and smaller than 5 mm. 
Statistical Analysis
Using analysis of variance with Bonferroni post-testing,
the mean numbers of reference-confirmed hepatic VX2 tu-
mors revealed by the two sonographic techniques were
compared with each other and with the number seen at
reference examination (gross pathologic examination) (17).
Using the paired t test, the size of the smallest VX2 tumor
detectable in each rabbit was compared between each
imaging technique. For statistical analysis of tumor detec-
tion rates, the McNemar test for correlated proportions
was used, with p values of less than 0.05 indicating a signif-
icant difference. Because of the small number of animals,
exact binomial probabilities were used in this test. The di-
agnostic accuracy of each imaging modality was compared
by calculating both sensitivity and specificity.
RESULTS
On examination of gross specimens, 52 VX2 tumors
were identified: 22 were less than 5 mm in diameter, 14
were between 5 and 9 mm, and 15 were 10 mm or larger.
In 15 of the 18 rabbits (83.3%) in which hepatic VX2 tu-
mors were seen at pathologic examination, conventional
imaging also revealed their presence (Table 1). In 61.1% of
the rabbits (11/18), more VX2 tumors were detected at PI-
HI with Levovist injection than at conventional US imag-
ing (Fig. 3). Of the 52 VX2 tumors, conventional US imag-
ing detected only 18 (34.6%), but PIHI with contrast injec-
tion detected 35 (67.3%) (p < 0.05). In addition, conven-
tional US and CE-PIHI revealed the presence of VX2 tu-
mors in 15 (83.3%) and 18 rabbits (100%), respectively,
with positive findings. Thus, sensitivity to the presence or
absence of hepatic VX2 tumor increased from 83.3% with
conventional US imaging to 100% with contrast-enhanced
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Fig. 1. A. Unenhanced baseline trans-
verse conventional US image obtained
in a rabbit shows a 10 mm, slightly hy-
perechoic hepatic VX2 tumor (arrows).
B. Transverse phase-inversion harmon-
ic US image obtained in the same ani-
mal five minutes after contrast injection
shows homogeneous enhancement of
normal liver parenchyma. Note the he-
patic VX2 tumor, seen as a well-defined
hypoechoic enhancement defect (ar-
rows). 
C. Transverse section of a gross speci-
men reveals an oval-shaped, whitish
VX2 liver tumor (arrows). 
A
C
BPIHI (p > 0.05). In three rabbits with false-negative find-
ings at conventional imaging, four tumors (two less than 5
mm in diameter, two between 5 and 9 mm) were found at
pathologic examination; contrast-enhanced PIHI detected
three of four nodules (Fig. 2). Furthermore, contrast-en-
hanced PIHI detected significantly smaller VX2 tumors
than did conventional US imaging (p < 0.05): the latter de-
picted 19 of 36 tumors less than 10 mm in diameter
(52.8%), while the former revealed only three such tumors
(8.3%) (Table 1).
Conventional US imaging showed that tumors were
characterized by isoechoic or slightly hyperechoic tissues;
because of signs of compression of surrounding liver
parenchyma and the formation of central necrosis and cyst-
like structures, those larger than 5 mm were, however, on-
ly partially visible (Fig. 1). The use of contrast-enhanced
PIHI led to marked hepatic parenchymal enhancement, i.e.
markedly increased liver echogenicity. Tumors were clear-
ly delineated as areas devoid of enhancement that ap-
peared as hypo- or nearly anechoic lesions (Fig. 1). The
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Fig. 2. A. Unenhanced subcostal trans-
verse sonogram of rabbit liver depicts a
heterogeneous isoechoic lesion (ar-
rows).
B.  Contrast-enhanced transverse
phase-inversion US image obtained
slightly inferior to the unenhanced image
(A) reveals three nonenhancing foci
measuring 2-12 mm in diameter. Two
additional lesions (arrows) are identified,
and their conspicuity is much greater
than at unenhanced conventional imag-
ing (A).
C. Transverse section of the liver re-
veals five tumors at the same location.
Compared to B, two additional lesions





Table 1. Detection Rates of Experimental VX2 Liver Tumors in Rabbits, Using Conventional and Contrast-Enhanced US
Technique
Tumor size (mm)
< 5mm 5 9 mm 10 mm
Total
Conventional sonography 00 (0) 03 (21.4) 15 (93.8) 18 (34.6)
CE phase-inversion sonography 06 (27.3) 13 (92.9) 16 (100) 35 (67.3)
Histopathologic Findings 22 (100) 14 (100) 16 (100) 52 (100)
Note. CE= ‘contrast-enhanced’. Numbers in parenthesis are percentages.conspicuity of tumors detected at both conventional US
and CE-PIHI was greater at CE-PIHI (Figs. 1 and 2). 
Data analysis showed that conventional imaging permit-
ted the correct identification of 18 of 52 tumors and all five
normal control animals. and its sensitivity and specificity
were thus 34.6% and 100%, respectively. Because 34
false-negative results were obtained at conventional US,
the difference between this modality and the pathologic
findings was significant (p < 0.001). At CE-PIHI, the num-
ber of false negatives was reduced to 17. The contrast-en-
hanced US findings were, however, significantly different
from those of pathology (p < 0.05): following the adminis-
tration of Levovist, sensitivity increased to 67%, and there
was thus significant difference between the sensitivity of
US with and without contrast agent (p < 0 .05). 
DISCUSSION
With the use of increasingly aggressive surgical tech-
niques for the management of liver metastases, the task of
preoperative imaging has become more demanding. To this
end, a variety of imaging modalities, including US, com-
puted tomography (CT) and magnetic resonance imag-
ing(MRI), have been used for the detection of hepatic
metastases (18,19), and in recent years, as contrast-specific
imaging modes such as wide-band harmonic imaging and
stimulated acoustic emission have developed, the use of
various sonographic contrast agents has gained popularity
(8-12, 20-24). Contrast-specific ultrasound imaging tech-
niques are highly sensitive to both microbubble movement
and microbubble collapse, independently of the level of
applied acoustic peak pressure. When increasing pressure
(high mechanical index), the microbubbles are destroyed,
leading to strong acoustic enhancement of the tissue con-
taining them (8-12). Compared to color Doppler harmonic
US, PIHI has a number of features advantageous for
parenchymal imaging: higher spatial and temporal resolu-
tion, and less motion artifact and contrast agent-induced
blooming (20-22). Previous studies (11,12,15,16) have in-
dicated that this strong acoustic enhancement of liver
parenchyma induced by PIHI during the late phase of
Levovist leads to improved detection of small liver tumors
by improving contrast between the tumors and liver
parenchyma (11,12,16). A limitation of those studies, how-
ever, was their lack of definitive pathologic proof. 
Contrast-enhanced PIHI proved particularly useful for
detecting small VX2 tumors (less than 10 mm in diameter)
that were often invisible on baseline images but became
apparent due to the marked increase in contrast between a
nonenhancing lesion and enhancing surrounding parenchy-
ma. Conventional imaging detected only three (8.3%) of
36 tumors less than 10 mm in diameter, while contrast-en-
hanced PIHI demonstrated 16 additional nodules (52.8%;
19/36) (p < 0.05). PIHI showed that during the late hepatic
phase of contrast enhancement with Levovist, hepatic
parenchymal enhancement was homogeneous in all rab-
bits, but hepatic VX2 tumors were clearly delineated as ar-
eas devoid of enhancement. Contrast between tumors and
liver parenchyma thus showed remarkable improvement at
contrast-enhanced PIHI compared to conventional US
imaging, suggesting that PIHI can increase the detectability
of small VX2 tumors. Although it is not yet clear precisely
where Levovist accumulates inside the liver, there is most
likely some form of non-phagocytic interaction with cells
of the reticuloendothelial system (11, 12, 24). The low rate
of detection of small lesions, one of the main limitations of
conventional sonography, was, therefore, overcome with
contrast-enhanced PIHI. Although it is still possible that tu-
mors less than 5 mm in diameter might not be detectable in
cirrhotic human liver, nor do CT and MR imaging detect
small tumors at rates which are satisfactorily high (4,6, 25).
The results of the present study with Levovist are, there-
fore, encouraging. 
However, even when PIHI and a contrast agent were
used, the detection rate of tumors smaller than 5 mm in di-
ameter was only 27.3% (6/22). In addition, contrast-en-
hanced PIHI revealed, in total, only 67.3% of hepatic VX2
tumors, a relatively poor result compared to that of a pre-
vious study using a different US contrast medium (20).
Forsberg et al. (14) stated that pulse-inversion harmonic
imaging using NC 100100 (Sonazoid; Amersham Health,
Oslo, Norway) detected 93% of hepatic VX2 tumors.
Although we cannot explain why our results were worse
than in that earlier study, the low detection rate associated
with contrast-enhanced US for VX2 tumors may be related
to the transient nature of late-phase enhancement with
Levovist. Using the current high-mechanical-index PIHI
technique, only part of the liver can be visualized in one or
two sweeps because of rapid bubble depletion. A potential
solution to this problem may be the use of recent low-me-
chanical-index techniques allowing several sweeps to be
performed using the same bubble population, or slow con-
trast infusions with continuous bubble replenishment (16). 
The major limitation of this study was that the lesion-to-
lesion comparison at unenhanced conventional US and
contrast-enhanced PIHI was sometimes difficult because of
the limited imaging planes used for PIHI during sweeping.
When correlating individual lesions, some degree of flexi-
bility was therefore required. When it was difficult to
match individual lesions, and both US examination modes
showed that their size and distribution were similar, we as-
sumed that they were identical. This approach is certainly
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This study demonstrated that phase-inversion sonogra-
phy during the late phase of contrast enhancement with
Levovist detects more hepatic VX2 tumors than conven-
tional sonography. We therefore believe that the use of
CE-PIHI can improve the detection of small human liver
tumors and that for liver imaging, this modality may be-
come a competitive alternative to modalities such as CT
and MR imaging. To compare the diagnostic performance
of PIHI with that of other imaging modalities, further study
is warranted.
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